✦ LIBER ✦

Tumor size is a major determinant of recurrence in patients with resectable gastrointestinal stromal tumor

✍ Scribed by Kai-Hsi Hsu; Ta-Ming Yang; Yan-Shen Shan; Pin-Wen Lin

Book ID: 116215747
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 220 KB
Volume: 194
Category: Article
ISSN: 0002-9610
DOI: 10.1016/j.amjsurg.2006.10.033

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Predictors of outcome in patients with r

Predictors of outcome in patients with recurrent gastrointestinal stromal tumors

✍ Jeremiah L. Deneve; Colin M. Parsons; Jongphil Kim; Anthony P. Conley; Jonathan 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 110 KB

Tu1088 Prediction of Tumor Recurrence in

Tu1088 Prediction of Tumor Recurrence in Patients With Gastrointestinal Stromal Tumors Following Resection by the Modified NIH Criteria

✍ Kwon, Ji Eun; Kim, Sang Gyun; Lim, Joo Hyun; Chun, Jaeyoung; Choi, Jeongmin; Im, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 415 KB

Imatinib mesylate–induced repigmentation

Imatinib mesylate–induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors

✍ Hui Han; Yang-yang Yu; Yu-hong Wang 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 176 KB

Monitoring of Loss of Heterozygosity in

Monitoring of Loss of Heterozygosity in Serum Microsatellite DNA Among Patients with Gastrointestinal Stromal Tumors Indicates Tumor Recurrence

✍ Tamina Rawnaq; Heidi Schwarzenbach; Paulus G. Schurr; Kathrin Freise; Stephan Br 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Resection of residual disease in patient

Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib

✍ Sebastian Bauer; Jörg Thomas Hartmann; Maike de Wit; Hauke Lang; Florian Grabell 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 723 KB

## Abstract Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Long‐term survival of patients with metastatic disease has only been observed in patients with completely resected disease. Recently, the tyrosine kinase inhibitor imatinib has b

Treatment of Gastrointestinal Stromal Tu

Treatment of Gastrointestinal Stromal Tumors with Imatinib Mesylate:A Major Breakthrough in the Understanding of Tumor-specific Molecular Characteristics

✍ Philippe de Mestier; Gaetan des Guetz 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 196 KB